Sunvozertinib achieved a statistically significant, clinically meaningful PFS advantage over platinum-based chemotherapy by ...
Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...
The 2026 IASLC Targeted Therapies in Lung Cancer meeting brought together leading oncologists, surgeons, and patient ...
According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...
Cemiplimab monotherapy offers quality-of-life benefits over chemotherapy in patients with advanced NSCLC and PD-L1 expression ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
A regimen based on Incyte's PD-1 inhibitor Zynyz and chemotherapy has become the first systemic treatment to be approved in the EU for advanced squamous cell carcinoma of the anal canal (SCAC). Zynyz ...
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR?)-targeting ...
A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research ...
Engaging in a simple home-based exercise regimen of walking and resistance training during chemotherapy can help patients ...
The likelihood that a person with early-stage non-small cell lung cancer will receive curative treatment still varies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results